Apollo Group of Hospitals on May 28 announced that they would offer Casirivimab and Imdevimab, popularly being called an ‘antibody cocktail’, to patients having mild and moderate Covid-19 symptoms and those who are highly exposed to the virus.
A cocktail of Casirivimab and Imdevimab could notably help the Covid-19 patients who are at high risk before their condition worsens, claimed the authority.
The combination of Casirivimab and Imdevimab, already being used in other countries like the US, is now available in India. Earlier, Roche India and Cipla had announced their launch in the country.
The day before, the Apollo Group on May 27 said that it would start administering Sputnik V, a Russian single-dose Covid-19 vaccine, across its hospitals in India beginning from the second week of June, at around Rs 1,195 per dose.
“We will be charging Rs 995 for the vaccine and Rs 200 for administration charges,” said an official from the Apollo Hospitals.
India is moving to vaccine sufficiency as vaccination with the Russian vaccine Sputnik V began in India earlier this month.
As per the latest reports, Indian and Russia are planning to manufacture nearly 35-40 million doses each month which is going to start between August and September.
The Russian Direct Investment Fund (RDIF) and Panacea Biotec (one of the leading pharmaceutical producers in India) on May 24 had started producing the Sputnik V Covid-19 vaccine.
The Russian vaccine got approval from the Subject expert committee (SEC) for Emergency Use Authorisation (EUA), making it the third Cobid-19 vaccine in India to get clearance.
India stands at number 60 to authorise the use of the Sputnik V vaccine against coronavirus. It has now approval from countries with a total population of 3 billion, which is 40% of the world’s population.
